← Back to Screener
Molecular Partners AG American Depositary Shares (MOLN)
Price$4.41
Favorite Metrics
Price vs S&P 500 (26W)7.92%
Price vs S&P 500 (4W)-12.54%
Market Capitalization$169.38M
All Metrics
Book Value / Share (Quarterly)$2.75
P/TBV (Annual)1.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-20.13%
Cash Flow / Share (Quarterly)$-1.78
Price vs S&P 500 (YTD)0.03%
Net Profit Margin (TTM)-866.56%
EPS (TTM)$-2.14
10-Day Avg Trading Volume0.03M
EPS Excl Extra (TTM)$-2.14
Revenue Growth (5Y)-24.59%
EPS (Annual)$-2.12
ROI (Annual)-73.41%
Gross Margin (Annual)99.80%
Net Profit Margin (5Y Avg)-646.31%
Cash / Share (Quarterly)$3.19
ROA (Last FY)-60.38%
EBITD / Share (TTM)$-1.95
ROE (5Y Avg)-31.87%
Operating Margin (TTM)-896.17%
Cash Flow / Share (Annual)$-1.78
P/B Ratio1.64x
P/B Ratio (Quarterly)1.70x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)6.21x
Net Interest Coverage (TTM)-16.57x
ROA (TTM)-54.64%
EV / EBITDA (TTM)0.21x
EPS Incl Extra (Annual)$-2.12
Current Ratio (Annual)8.79x
Quick Ratio (Quarterly)8.61x
3-Month Avg Trading Volume0.03M
52-Week Price Return-39.30%
EV / Free Cash Flow (Annual)-0.88x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.75
P/S Ratio (Annual)26.56x
Asset Turnover (Annual)0.03x
52-Week High$4.14
Operating Margin (5Y Avg)-662.57%
EPS Excl Extra (Annual)$-2.12
CapEx CAGR (5Y)-15.76%
Tangible BV CAGR (5Y)-5.55%
26-Week Price Return16.67%
Quick Ratio (Annual)8.61x
13-Week Price Return9.72%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)8.79x
Enterprise Value$68.015
Revenue / Share Growth (5Y)-31.27%
Asset Turnover (TTM)0.05x
Book Value / Share Growth (5Y)-10.21%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-1087.34%
Cash / Share (Annual)$3.19
3-Month Return Std Dev71.25%
Gross Margin (5Y Avg)98.50%
Net Income / Employee (TTM)$-1
ROE (Last FY)-76.74%
Net Interest Coverage (Annual)-12.36x
EPS Basic Excl Extra (Annual)$-2.12
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.05x
EPS Incl Extra (TTM)$-2.14
Receivables Turnover (Annual)0.00x
ROI (TTM)-63.88%
P/S Ratio (TTM)15.45x
Pretax Margin (5Y Avg)-646.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.75
Price vs S&P 500 (52W)-37.36%
Year-to-Date Return3.40%
5-Day Price Return9.03%
EPS Normalized (Annual)$-2.12
ROA (5Y Avg)-23.54%
Net Profit Margin (Annual)-1087.38%
Month-to-Date Return12.18%
Cash Flow / Share (TTM)$-1.16
EBITD / Share (Annual)$-1.93
Operating Margin (Annual)-1231.73%
LT Debt / Equity (Annual)1.55x
ROI (5Y Avg)-30.50%
LT Debt / Equity (Quarterly)1.48x
EPS Basic Excl Extra (TTM)$-2.14
P/TBV (Quarterly)1.70x
P/B Ratio (Annual)1.70x
Pretax Margin (TTM)-866.56%
Book Value / Share (Annual)$2.75
Price vs S&P 500 (13W)6.85%
Beta0.66x
P/FCF (Annual)1.13x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.47%
52-Week Low$2.71
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MOLNMolecular Partners AG American Depositary Shares | 15.45x | — | — | — | $4.41 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company developing DARPin therapeutics—protein-based drugs targeting serious diseases across three main pipeline areas: oncology, ophthalmology, and immuno-oncology. The company's ophthalmology programs focus on retinal diseases including wet age-related macular degeneration and diabetic macular edema, while its oncology candidates employ novel multi-DARPin compounds with differentiated mechanisms of action. With oncology as its primary therapeutic focus, Molecular Partners advances a pipeline of DARPin-based treatments designed to address significant medical needs in cancer and sight-threatening disorders.